Cancer-related fatigue and associated disability in post-treatment cancer survivors
the ONA take:
Cancer-related fatigue (CRF) is the most common symptom for patients with cancer. However, data on its prevalence in the posttreatment period is limited.
Using a self-administered mail-based questionnaire, these researchers sought to measure occurrence of CRF in three cohorts (16 to 18 months posttreatment, 2 to 3 years posttreatment, and 5 to 6 years posttreatment) of disease-free survivors of breast, prostate, or colorectal cancer.
The study generated a 63% response rate (2,294 questionnaire packages were returned). Twenty-nine percent of respondents reported significant fatigue, although fatigue levels did not differ between time cohorts.
Reports of fatigue were significantly higher in survivors of breast or colorectal cancer compared with survivors of prostate cancer.
The researchers conclude that approximately one-third of cancer survivors experience fatigue for up to 6 years after treatment. Clinicians should be aware that fatigue can be a chronic condition, and should routinely assess for it.
Cancer-related fatigue is the most common symptom for patients with cancer.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|